# Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

Study · id `cardio:ct-nct01647542` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01647542](<https://clinicaltrials.gov/study/NCT01647542>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01647542

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 393 participants.

## Technical summary

Registry record NCT01647542. Randomized; quadruple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2015-08-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 393 participants (enrolled count; ClinicalTrials.gov record NCT01647542, source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01647542, source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)
- Primary completion: 2014-02 (actual) (ClinicalTrials.gov record NCT01647542, source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)
- Completion: 2014-03 (actual) (ClinicalTrials.gov record NCT01647542, source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)
- Results first posted: 2015-08-19 (ClinicalTrials.gov record NCT01647542, source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)
- Countries: Australia; China; New Zealand; South Korea; Taiwan (ClinicalTrials.gov record NCT01647542, source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01647542-2015-11-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
- Acronym: GRAND-307
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): TAK-875
- Intervention (Drug): TAK-875 Placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 9409571a3004a7c22b1de8c37efdda66004577dbd9683c43f494ab262f30570f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
